EMA to relax requirements for biosimilar G-CSF
This article was originally published in SRA
Executive Summary
The European Medicines Agency is proposing to ease the clinical and non-clinical study requirements for companies developing biosimilar granulocyte-colony stimulating factor (G-CSF) products to take account of experience gained in this field and bring the requirements into line with changes to the agency's general biosimilars guidance1.